Senesco Technologies Inc.

ELOX Healthcare Biotechnology

Senesco Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $6.4 million. In the quarter to June 2026, EPS grew 87.7% and free cash flow fell 144.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

13.03 0.67 −4.89%
Market cap
$55.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Jun '25 Older periods
ROE
(89.91%) 78.27% 0.00% 0.00%

+8 more TTM periods

ROA
(34.15%) (141.35%) 0.00% (336.49%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(25.54%) 135.09% 0.00% 0.00%
Free Cash Flow per Share
(1.59) (1.83) — (17.32)
Free Cash Flow
(10.79) (8.01) — (6.01)
Other line items
Cash ROIC
(9.96%) 659.51% 0.00% 0.00%
Accounts Payable Turnover
0.00 0.00 0.00 —
Average Days of Payables
0.00 0.00 0.00 —
Tax Rate
0.00 0.00 — 0.00
Research and Development Expense of Revenue
0.00% 0.00% — 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% — 0.00%
Share Based Compensation of Revenue
0.00% 0.00% — 0.00%
Operating CF/Net income
0.91 0.78 — 0.60
Depreciation/Fixed assets
0.00 0.00 — 0.00
Capex/Depreciation
0.00 0.00 — 0.00
Revenue per Share
0.00 0.00 — 0.00
Operating CF per Share
(1.59) (1.83) — (17.32)
Capex per Share
0.00 0.00 — 0.00

Fold the line items

Columns are period end dates